In recent years, inhibitors targeting PI3K/AKT signaling have been shown to reduce the tumor burden in different experimental models and have been considered as potential therapeutic agents (Johnson et al., 2010; Narayanankutty, 2019). Here, AKT1 is linked to neoplasm.